Johnson & Johnson (JNJ) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Johnson & Johnson (JNJ)

250.61

+1.79 (0.72%)

as of Jul 21, 2026, 8:00:00 pm Market Open.

697 watching

Investor Insights

Jul 21, 2026, 12:00 am

This summary was created by AI, based on 10 opinions in the last 12 months.

Johnson & Johnson (JNJ) has shown strong performance in the pharmaceutical sector, particularly after spinning off its orthopedics division. Despite challenges in the cardio business and ongoing talcum-cancer lawsuits, expert opinions are largely optimistic about the company's future prospects. The current focus on high-margin areas like medical devices and pharmaceuticals, combined with a strong drug pipeline, positions JNJ for growth. Although the stock may experience fluctuations around earnings reports, it is generally viewed as a buy during dips. Overall, experts suggest that JNJ remains a sound investment, particularly for those interested in dividend growth and potential additional upside.

Consensus

Buy

Valuation

Fair Value

Similar

PAST TOP PICK

(A Top Pick Aug 25/09. Down 3.12%.) Ran into some problems with some product recalls but it is still etched in the cheap.

BUY

Currency is an important aspect when buying a US stock but you also want to look for a higher rate of return to compensate for the currency risk. This is a great company with a great ROE and a decent yield. Long-term hold.

TOP PICK

Good way to diversify your portfolio. Nice blend of businesses in terms of pharmaceutical and medical devices. Stock has had a lot of headline problems that has really taken the shares down. Good record of dividend increases and strong balance sheet.

BUY

Diagnostics is probably a good area to consider.

BUY

Great company, great price. Trading at 11X next year's earnings. Dividends on US companies are taxed at the full marginal rate, something like interest rates. As well there is with holding tax charged prior to the receipt of them.

BUY

About one third is Pharma but also has a consumer side and diagnostics. Well diversified. Strong balance sheet and trading at about 11.5-12 times earnings. Good dividend.

DON'T BUY

He is avoiding all US stocks. It’s a great stock for a US account.

BUY

Has some pharma exposure but they have diversification with their consumer and diagnostic businesses. Prefers this to the pure Pharma plays. Good dividend and trades at a multiple of the low teens. Good growth metrics.

BUY

Healthcare companies have not participated in the market run up but, if you are going into a time of market weakness, stocks like this will do well both relatively and absolutely here.

BUY

Has a good presence in emerging markets both in its Pharma business and medical devices. One of the few healthcare firms where management has an overall financial objective. Have raised dividends for 50 some odd years.

DON'T BUY

One of the stronger names in the healthcare space but this might not be the best performing sector. Chart looks quite nice moving along the 50 day moving average. 3% yield with a 40% payout ratio.

PAST TOP PICK

(A Top Pick March 26/09. Up 22.2% excluding dividends.) Trading at one of its lowest historic multiples. 3% yield. The pure pharma companies are suffering from a lack of new drugs but this one is well diversified.

PAST TOP PICK

(Top Pick Feb 23/09, Up 20%) Held it a very long time. They are very unique in that they are a pharma company, a personal care company and medical devices company. They trade at a relatively low PE ratio. A very consistent company that will grow between 10 and 15% yearly.

PAST TOP PICK

(Top Pick Jul 3/09, Up 14.83%) Would still buy.

TOP PICK

Indicative of why investors need to invest outside of Canada. Has a multi-decade record of dividend increases. Regulatory issues are behind it. Low double-digit earnings growth over the next couple of months. Well run. Business: 2/5ths from pharma 2/5ths medical devices and 1/5th consumer health care.

Showing 451 to 465 of 628 entries

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Julien Nono-Womdim

Goodreid Investment Council

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

David Driscoll

Liberty International Investment Management Inc

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Johnson & Johnson (JNJ)